

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal621vx0

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 12 Match STN Content and Features to Your Information
Needs, Quickly and Conveniently
NEWS 3 JAN 25 Annual Reload of MEDLINE database
NEWS 4 FEB 16 STN Express Maintenance Release, Version 8.4.2, Is
Now Available for Download
NEWS 5 FEB 16 Derwent World Patents Index (DWPI) Revises Indexing
of Author Abstracts
NEWS 6 FEB 16 New FASTA Display Formats Added to USGENE and PCTGEN
NEWS 7 FEB 16 INPADOCDB and INPAFAMDB Enriched with New Content
and Features
NEWS 8 FEB 16 INSPEC Adding Its Own IPC codes and Author's E-mail
Addresses
NEWS 9 APR 02 CAS Registry Number Crossover Limits Increased to
500,000 in Key STN Databases
NEWS 10 APR 02 PATDPAFULL: Application and priority number formats
enhanced
NEWS 11 APR 02 DWPI: New display format ALLSTR available
NEWS 12 APR 02 New Thesaurus Added to Derwent Databases for Smooth
Sailing through U.S. Patent Codes
NEWS 13 APR 02 EMBASE Adds Unique Records from MEDLINE, Expanding
Coverage back to 1948
NEWS 14 APR 07 CA/Caplus CLASS Display Streamlined with Removal of
Pre-IPC 8 Data Fields
NEWS 15 APR 07 50,000 World Traditional Medicine (WTM) Patents Now
Available in Caplus
NEWS 16 APR 07 MEDLINE Coverage Is Extended Back to 1947
NEWS 17 JUN 16 WPI First View (File WPIFV) will no longer be
available after July 30, 2010
NEWS 18 JUN 18 DWPI: New coverage - French Granted Patents
NEWS 19 JUN 18 CAS and FIZ Karlsruhe announce plans for a new
STN platform
NEWS 20 JUN 18 IPC codes have been added to the INSPEC backfile
(1969-2009)
NEWS 21 JUN 21 Removal of Pre-IPC 8 data fields streamline displays
in CA/Caplus, CASREACT, and MARPAT
NEWS 22 JUN 21 Access an additional 1.8 million records exclusively
enhanced with 1.9 million CAS Registry Numbers --
EMBASE Classic on STN
NEWS 23 JUN 28 Introducing "CAS Chemistry Research Report": 40 Years

10/923,271

of Biofuel Research Reveal China Now Atop U.S. in
Patenting and Commercialization of Bioethanol
NEWS 24 JUN 29 Enhanced Batch Search Options in DGENE, USGENE,
and PCTGEN
NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:03:51 ON 18 JUL 2010

=> file reg	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	0.44	0.44

FILE 'REGISTRY' ENTERED AT 17:04:50 ON 18 JUL 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2010 HIGHEST RN 1232397-02-2
DICTIONARY FILE UPDATES: 15 JUL 2010 HIGHEST RN 1232397-02-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

10/923,271


Uploading C:\Program Files\Stnexp\Queries\10657910a.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,N

G2 C,H,Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 191.05 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 17:06:12 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 206298 TO ITERATE

100.0% PROCESSED 206298 ITERATIONS

124 ANSWERS

SEARCH TIME: 00.00.05

L2 124 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

192.52

192.96

FILE 'CAPLUS' ENTERED AT 17:06:22 ON 18 JUL 2010

Toh

18/07/2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jul 2010 VOL 153 ISS 4
FILE LAST UPDATED: 16 Jul 2010 (20100716/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2010

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l2 and py<2004
      11 L2
      24051329 PY<2004
L3      2 L2 AND PY<2004
```


```
=> d l-2 ibib abs hitstr
THE ESTIMATED COST FOR THIS REQUEST IS 11.62 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y
```

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN


```
ACCESSION NUMBER: 2004:964817 CAPLUS
DOCUMENT NUMBER: 141:410756
TITLE: Preparation of macrocyclic compounds for the treatment
of inflammation and autoimmune disorders
INVENTOR(S): Chiba, Kenichi; Du, Hong; Eguchi, Yoshihito; Fujita,
Masanori; Goto, Masaki; Gusovsky, Fabian; Harmange,
Jean-Christophe; Inoue, Atsushi; Kawada, Megumi;
Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura,
Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Matsushima,
Tomohiro; Mizui, Yoshiharu; Muramoto, Kenzo; Sakurai,
Hideki; Shen, Yong-chun; Shirota, Hiroshi; Spyvee,
Mark; Tanaka, Isao; Wang, John; Wood, Ray; Yamamoto,
Satoshi; Yoneda, Naoki
PATENT ASSIGNEE(S): Japan
SOURCE: U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of Appl.
No. PCT/US03/07377.
```

DOCUMENT TYPE: CODEN: USXXCO
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040224936	A1	20041111	US 2003-657910	20030909
WO 2003076424	A1	20030918	WO 2003-US7377	20030307 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ZA 2004007156	A	20061227	ZA 2004-7156	20040907
WO 2005023792	A2	20050317	WO 2004-US29196	20040909
WO 2005023792	A3	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2008297317	A	20081211	JP 2008-194192	20080728
PRIORITY APPLN. INFO.:				
			US 2002-362883P	P 20020308
			US 2002-380711P	P 20020514
			WO 2003-US7377	A2 20030307
			JP 2003-574642	A3 20030307
			US 2003-657910	A 20030909
OTHER SOURCE(S): CASREACT 141:410756; MARPAT 141:410756				
GI				



I



II

AB Macrocyclic compds. of formula I [R1 = H, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.; R2, R3 = H, halo, (substituted) OH, alkyl, aryl, etc.; R1R2, R1R3 = alkylene; R4 = H, halo; R5 = H, protecting group, prodrug; R6, R7, R11 = H, (substituted) OH; R8, R9 = H, halo, (substituted) OH, alkoxy, etc.; R10 = H, (substituted) OH, (substituted) NH2; n = 0-2; X = absent, O, NH, N-alkyl, CH2, S; Y, Z = CH, O, CO, NH, etc.] are prepared for the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis. In certain embodiments, methods for the treatment of various disorders including inflammatory or autoimmune disorders comprise systemically (e.g., orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formula I. Thus, II was prepared in several steps. Some of the compds. inhibited NF- κ B with IC50 values < 10 μ M.

IT 603039-45-8P 603045-38-1P 603045-40-5P
 603045-42-7P 603045-44-9P 603045-46-1P
 603151-24-2P 603151-32-2P 603151-34-4P
 603959-45-1P 603985-37-1P 603985-63-3P
 603985-65-5P 603985-69-9P 603985-71-3P
 603985-72-4P 603985-73-5P 603985-74-6P
 603985-75-7P 603985-77-9P 603985-78-0P
 603986-04-5P 603987-34-4P 603987-35-5P
 603987-75-3P 603987-93-5P 603988-36-9P
 791101-13-8P 791101-14-9P 791101-15-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of macrocyclic compds. for the treatment of inflammatory or autoimmune disorders)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-
 (trifluoromethyl)-, (5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-38-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
 14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


10/923,271

Absolute stereochemistry.
Double bond geometry as shown.




RN 603045-40-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603045-42-7 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-
3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




10/923,271

RN 603045-44-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-
dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-46-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-24-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603959-45-1 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-
, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-37-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-63-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

10/923,271




RN 603985-65-5 CAPLUS

CN Acetamide, N-[3-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-69-9 CAPLUS

CN Acetamide, N-[3-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-71-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(
(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-72-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-73-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-
pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-74-6 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-75-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



=O

RN 603985-77-9 CAPLUS
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
 3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-
 ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX
 NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



=O

RN 603985-78-0 CAPLUS
 CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
 14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
 (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 603986-04-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-
trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603987-35-5 CAPLUS

10/923,271


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603987-75-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-93-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-
(methylamino)-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603988-36-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-
dimethyl-, (3S,4R,5Z,8S,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 791101-13-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



10/923,271


RN 791101-14-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(
(methyamino)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 791101-15-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-[2-(dimethylamino)ethoxy]-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:737744 CAPLUS

DOCUMENT NUMBER: 139:261090

TITLE: Preparation of macrocyclic compounds for use in
pharmaceutical and cosmetic compositions which
regulate various genes involved in immune and
inflammatory responses

INVENTOR(S): Boivin, Roch; Chiba, Kenichi; Davis, Heather A.;
Diepito, Lucian; Du, Hong; Eguchi, Yoshineto; Fujita,
Masanori; Gilbert, Sandra; Goto, Masaki; Harmange,
Jean Christophe; Inoue, Atsushi; Jiang, Yimin; Kawada,

Megumi; Kawai, Takatoshi; Kawakami, Yoshiyuki; Kimura, Akifumi; Kotake, Makoto; Kuboi, Yoshikazu; Lemelin, Charles; Li, Xiang-yi; Matsushima, Tomohiro; Mizui, Yoshiharu; Sakurai, Hideki; Schiller, Shawn; Shen, Yongchun; Spyvee, Mark; Tanaka, Isao; Wang, Yuan; Yamamoto, Satoshi; Yoneda, Naoki; Kobayashi, Seiichi
 Eisai Co. Ltd., Japan; et al.
 PCT Int. Appl., 438 pp.

PATENT ASSIGNEE(S):

SOURCE:

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076424	A1	20030918	WO 2003-US7377	20030307 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2478065	A1	20030918	CA 2003-2478065	20030307 <--
AU 2003224672	A1	20030922	AU 2003-224672	20030307 <--
AU 2003224672	B2	20100204		
BR 2003008113	A	20050209	BR 2003-8113	20030307
EP 1507773	A1	20050223	EP 2003-721353	20030307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005519954	T	20050707	JP 2003-574642	20030307
CN 1653059	A	20050810	CN 2003-810248	20030307
NZ 535101	A	20070727	NZ 2003-535101	20030307
RU 2334744	C2	20080927	RU 2004-129755	20030307
US 20040224936	A1	20041111	US 2003-657910	20030909
IN 2004KN01270	A	20060714	IN 2004-KN1270	20040830
ZA 2004007156	A	20061227	ZA 2004-7156	20040907
MX 2004008722	A	20050713	MX 2004-8722	20040908
NO 2004004256	A	20041207	NO 2004-4256	20041007
US 20060247448	A1	20061102	US 2004-507067	20041110
JP 2008297317	A	20081211	JP 2008-194192	20080728
AU 2010201776	A1	20100527	AU 2010-201776	20100504
PRIORITY APPLN. INFO.:			US 2002-362883P	P 20020308
			US 2002-380711P	P 20020514
			AU 2003-224672	A3 20030307
			JP 2003-574642	A3 20030307
			WO 2003-US7377	W 20030307

OTHER SOURCE(S):

MARPAT 139:261090

GI



AB Macrocylic lactones and lactams, such as I [R₁ = H, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R₂, R₃ = H, OH, halogen, protected hydroxyl, alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl; R₁R₂ or R₁R₃ = 3-8 membered alicyclic ring; R₄ = H, halogen; R₅ = H, hydroxyl protecting group, linked prodrug; R₆, R₇ = H, OH, protected hydroxyl; R₈, R₉, R₁₀, R₁₁ = H, OH, NH₂, alkoxy, alkylamino, etc.; X = O, NH, S, CH₂, etc.; R₈R₉ = fused ring, such as furan or imidazole; Y-Z = CH:CH, NHCO, etc.], were prepared for a variety of therapeutic and cosmetic uses, such as antitumor and anti-inflammatory agents and treatment of skin photodamage. These macrocycles are claimed for use as NF-κB, AP-1, protein kinase, cancer cell proliferation and solid tumor angiogenesis inhibitors and for use in the treatment of inflammation, cancer, psoriasis, skin photodamage, restenosis as stent coatings, rheumatoid arthritis, asthma, sepsis, inflammatory bowel disease, atopic dermatitis, Crohn's disease, autoimmune disorders and for treatment of gastrointestinal, esophageal, tracheal/bronchial, urethral and vascular obstructions wherein the lumen of a body passageway is expanded. Thus, macrocyclic lactone II, designated as ER 803064, was prepared via a multistep synthetic sequence with included a macrolactonization reaction of III to form the desired lactone ring. The prepared macrocycles were assayed for their effect on TNF-α and β-actin placental alkaline phosphatase transcription using human acute monocytic leukemia cells.

IT	791101-13-8	1080810-60-1	1080810-61-2
	1080810-62-3	1080810-64-5	1080810-65-6
	1080810-66-7	1080810-68-9	1080810-70-3
	1080810-71-4	1080810-72-5	1080810-73-6
	1080810-74-7	1080810-75-8	1080810-76-9
	1080810-77-0	1080810-78-1	1080810-79-2

1080810-80-5	1080810-81-6	1080810-82-7
1080810-83-8	1080810-84-9	1080810-85-0
1080810-86-1	1080810-87-2	1080810-88-3
1080810-89-4	1080810-90-7	1080810-91-8
1080810-92-9	1080810-93-0	1080810-95-2
1080810-96-3	1080810-97-4	1080810-98-5
1080810-99-6	1080811-01-3	1080811-02-4
1080811-03-5	1080811-04-6	1080811-05-7
1080811-06-8	1080811-07-9	1080811-08-0
1080811-09-1	1080811-10-4	1080811-11-5
1080811-12-6	1083006-06-7	1198575-07-3

RL: PRPH (Prophetic)


(Preparation of macrocyclic compounds for use in pharmaceutical and cosmetic compositions which regulate various genes involved in immune and inflammatory responses)

RN 791101-13-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-ethoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 1080810-60-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

Double bond geometry as shown.




RN 1080810-61-2 CAPLUS

10/923,271

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-62-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-64-5 CAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080810-65-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-66-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-68-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080810-70-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-71-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-72-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as described by E or Z.



10/923,271


RN 1080810-73-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-74-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-75-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080810-76-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-77-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-78-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080810-79-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-80-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-81-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-A




RN 1080810-82-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.





RN 1080810-83-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2-(1H-1,2,3-triazol-
1-yl)ethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-84-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-85-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-86-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-87-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
 Double bond geometry as described by E or Z.



RN 1080810-88-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
 Double bond geometry as shown.


PAGE 1-A






RN 1080810-89-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-90-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080810-91-8 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-92-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-93-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080810-95-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-96-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080810-97-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080810-98-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080810-99-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-01-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080811-02-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-03-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-04-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.

10/923,271




RN 1080811-05-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-06-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-butoxy-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080811-07-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(1-methylethoxy)-,

10/923,271


(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 1080811-08-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-09-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



10/923,271


RN 1080811-10-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as described by E or Z.




RN 1080811-11-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1080811-12-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.
Double bond geometry as shown.




10/923,271

RN 1083006-06-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.
Double bond geometry as shown.



RN 1198575-07-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4,4-dimethyl-,
(5Z,8S,9S,11E)- (CA INDEX NAME)



IT 603044-46-8P 603045-38-1P 603045-40-5P
603045-42-7P 603045-44-9P, ER 807563
603045-45-0P 603045-46-1P 603151-24-2P, ER
803064 603151-32-2P 603151-34-4P, ER 804019
603959-46-2P, ER 804035 603985-37-1P
603985-63-3P 603985-64-4P 603985-65-5P
603985-69-9P 603985-70-2P, ER 804606
603985-72-4P 603985-73-5P 603985-74-6P
603985-75-7P 603985-76-8P 603985-77-9P
603985-78-0P 603986-04-5P, ER 804387
603987-34-4P 603987-35-5P 603987-75-3P
603987-93-5P, ER 806821 603988-36-9P

RL: COS (Cosmetic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses)

RN 603044-46-8 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-

(methylamino)-, (3S,4R,5E,8R,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-38-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(dimethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-40-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-[(2-hydroxyethyl)amino]-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-42-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(2-hydroxyethyl)amino]-
3,4-dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-44-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-
dimethyl-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-45-0 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-
[(methylsulfonyl)oxy]propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603045-46-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-(1H-imidazol-1-yl)ethoxy]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-24-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-32-2 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603151-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
4-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4S,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603959-46-2 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-4-methyl-,
(4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-37-1 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-13,14-dimethoxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-63-3 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[(4-methoxyphenyl)methoxy]-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

10/923,271




RN 603985-64-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(2,3-dihydroxypropoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-
dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-65-5 CAPLUS

CN Acetamide, N-[3-[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-
trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-
oxopropyl]- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 603985-69-9 CAPLUS


CN Acetamide, N-[3-[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-yl]oxy]-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-70-2 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[2-(4-morpholinyl)ethoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-72-4 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,14,16-tetrahydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603985-73-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-(2-
pyridinylamino)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-74-6 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(2-azidoethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-75-7 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[2-[(1H-imidazol-2-
ylmethyl)amino]ethoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

=O

RN 603985-76-8 CAPLUS

CN Methanesulfonamide, N-[2-[[[(3S,4R,5Z,8S,9S,11E)-3,4,7,8,9,10-hexahydro-
8,9,16-trihydroxy-3,4-dimethyl-1,7-dioxo-1H-2-benzoxacyclotetradecin-14-
yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603985-77-9 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-[4-[(1H-imidazol-2-
ylmethyl)amino]butoxy]-3,4-dimethyl-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX
NAME)

Absolute stereochemistry.
Double bond geometry as shown.




PAGE 1-B

=O


RN 603985-78-0 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(difluoromethoxy)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603986-04-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(2,2,2-trifluoroethoxy)-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-34-4 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-(methylamino)-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-35-5 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
14-(ethylamino)-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-,
(3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 603987-75-3 CAPLUS


CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3,4-dimethyl-,
(3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 603987-93-5 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
6-fluoro-3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-
(methylamino)-, (3S,4R,5E,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 603988-36-9 CAPLUS
CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-10-(methoxymethoxy)-3,4-
dimethyl-, (3S,4R,5E,8S,9R,11E)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 603039-45-8P 603959-45-1P 603985-71-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of macrocyclic compds. for use in pharmaceutical and cosmetic compns. which regulate various genes involved in immune and inflammatory responses)

RN 603039-45-8 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-
(trifluoromethyl)-, (5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603959-45-1 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-4-(phenylmethyl)-
, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 603985-71-3 CAPLUS

CN 1H-2-Benzoxacyclotetradecin-1,7(8H)-dione,
3,4,9,10-tetrahydro-8,9,16-trihydroxy-3,4-dimethyl-14-[3-
(methylsulfonyl)propoxy]-, (3S,4R,5Z,8S,9S,11E)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT